Monoclonal Antibodies Generation: Updates and Protocols on Hybridoma Technology

1Citations
Citations of this article
3Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Since its inception in 1975, the hybridoma technology revolutionized science and medicine, facilitating discoveries in almost any field from the laboratory to the clinic. Many technological advancements have been developed since then, to create these “magical bullets.” Phage and yeast display libraries expressing the variable heavy and light domains of antibodies, single B-cell cloning from immunized animals of different species including humans or in silico approaches, all have rendered a myriad of newly developed antibodies or improved design of existing ones. However, still the majority of these antibodies or their recombinant versions are from hybridoma origin, a preferred methodology that trespass species barriers, due to the preservation of the natural functions of immune cells in producing the humoral response: antigen specific immunoglobulins. Remarkably, this methodology can be reproduced in small laboratories without the need of sophisticate equipment. In this chapter, we will describe the most recent methods utilized by our Monoclonal Antibodies Core Facility at the University of Texas–M.D. Anderson Cancer Center. During the last 10 years, the methods, techniques, and expertise implemented in our core had generated more than 350 antibodies for various applications.

Cite

CITATION STYLE

APA

Muhsin, A., Rangel, R., Vien, L., & Bover, L. (2022). Monoclonal Antibodies Generation: Updates and Protocols on Hybridoma Technology. In Methods in Molecular Biology (Vol. 2435, pp. 73–93). Humana Press Inc. https://doi.org/10.1007/978-1-0716-2014-4_6

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free